Does Kansas Medicaid cover GLP-1s for weight loss?
Does Kansas Medicaid cover GLP-1s for weight loss?
Kansas Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". On what has to be tried or preferred first: Saxenda, Wegovy and Zepbound each need prior authorization; a non-preferred choice needs written clinical rationale, and the treatment plan has to include diet and physical activity. Those criteria are quoted from KDHE Anti-Obesity Medications Prior Authorization Form, read directly rather than summarized from an aggregator. Where the answer is no, the cheapest verified cash route on this site is $129 a month (compounded, not FDA approved; FDA warning letter). The status above is read from the state's own published document rather than a national summary. Last checked 2026-09-05.
What the prior authorization asks for
- BMI threshold
- The form records the BMI and at least one weight-related comorbidity off the state's own list — type 2 diabetes, dyslipidemia, hypertension, sleep apnea, NASH, PCOS, GERD and a dozen more. For 12–17 year olds it is the 95th percentile for age and sex. The one number the form prints, a BMI of 40 or more (at 12–17, 40 or 140% of the 95th percentile), applies only to the 'high cost' agents in Table 4 of the clinical criteria — and the form states that Zepbound has not been in that table since 1 April 2024, nor Wegovy since 1 June 2025.
- Tried first
- Saxenda, Wegovy and Zepbound each need prior authorization; a non-preferred choice needs written clinical rationale, and the treatment plan has to include diet and physical activity.
Kansas keeps the numeric cut for the preferred agents in a separate clinical-criteria document, which the form links to at kdhe.ks.gov/206. That page would not open for us on 5 September 2026 — the state's site refused every attempt — so the cut is not recorded here rather than guessed.
Both tools fill from these criteria rather than from a template — a prior authorization for Kansas, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever Kansas decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: KDHE Anti-Obesity Medications Prior Authorization Form , effective 2025-06-01. Read on 2026-09-05. Fee-for-service rules; a managed-care plan in Kansas can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.